Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aptose Biosciences, Inc. - Common Shares
(NQ:
APTO
)
0.2790
+0.1088 (+63.92%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
306,245,549
Open
0.2700
Bid (Size)
0.2250 (154)
Ask (Size)
0.2300 (49)
Prev. Close
0.1702
Today's Range
0.2106 - 0.3895
52wk Range
0.1300 - 2.680
Shares Outstanding
93,653,662
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
December 20, 2024
Via
Benzinga
Aptose Announces Positive Decision by Nasdaq Hearings Panel
December 19, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Performance
YTD
-88.28%
-88.28%
1 Month
+14.34%
+14.34%
3 Month
-32.67%
-32.67%
6 Month
-62.40%
-62.40%
1 Year
-87.97%
-87.97%
More News
Read More
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
December 12, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
December 09, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
December 03, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
November 25, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
November 25, 2024
Via
Benzinga
S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results
November 22, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Crude Oil Gains Over 1%; Ross Stores Earnings Top Views
November 22, 2024
Via
Benzinga
Exposures
Fossil Fuels
Dow Jumps 300 Points; Gap Posts Upbeat Earnings
November 22, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
November 22, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
November 22, 2024
Via
Benzinga
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
November 20, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Third Quarter 2024
November 08, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Results from Special Meeting of Shareholders
September 05, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
September 03, 2024
Via
Benzinga
Hello Group, Zscaler And 3 Stocks To Watch Heading Into Tuesday
September 03, 2024
Via
Benzinga
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
August 30, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Adjournment of its Special Meeting of Shareholders
August 15, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q2 2024
August 09, 2024
Via
InvestorPlace
Aptose Reports Results for the Second Quarter 2024
August 08, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Receipt of Deficiency Notice from Nasdaq
July 19, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Results from Annual and Special Meeting of Shareholders
June 18, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
June 14, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 03, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.